NASDAQ:NLTX

Neoleukin Therapeutics - NLTX Stock Forecast, Price & News

$0.60

+0.02 (+3.48%)

(As of 01/31/2023 12:00 AM ET)

Add

Compare

Today's Range: $0.58
▼
$0.60
50-Day Range: $0.41
▼
$0.61
52-Week Range: $0.38
▼
$3.84

Volume: 42,115 shs
Average Volume: 133,816 shs
Market Capitalization: $25.34 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.00

Institutional Ownership

Neoleukin Therapeutics MarketRank™ Forecast

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 916.4% Upside
$6.00 Price Target
Short Interest: Healthy
0.70% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.04) to ($0.65) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.71 out of 5 stars

Medical Sector

75th out of 1,055 stocks

Pharmaceutical Preparations Industry

25th out of 518 stocks

4.0

Analyst's Opinion

Consensus Rating
Neoleukin Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 6 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $6.00, Neoleukin Therapeutics has a forecasted upside of 916.4% from its current price of $0.59.
Amount of Analyst Coverage
Neoleukin Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

5.0

Short Interest

Percentage of Shares Shorted
0.70% of the float of Neoleukin Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Neoleukin Therapeutics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Neoleukin Therapeutics has recently decreased by 14.79%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Neoleukin Therapeutics does not currently pay a dividend.
Dividend Growth
Neoleukin Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NLTX.

3.3

News and Social Media Coverage

News Sentiment
Neoleukin Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Neoleukin Therapeutics this week, compared to 0 articles on an average week.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Neoleukin Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
13.76% of the stock of Neoleukin Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
43.97% of the stock of Neoleukin Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Neoleukin Therapeutics are expected to grow in the coming year, from ($1.04) to ($0.65) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Neoleukin Therapeutics is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Neoleukin Therapeutics is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Neoleukin Therapeutics has a P/B Ratio of 0.18. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Neoleukin Therapeutics (NASDAQ:NLTX) Stock

Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA.

Receive NLTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neoleukin Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NLTX Stock News Headlines

December 12, 2022 | finance.yahoo.com

Neoleukin Therapeutics Presents Preclinical Data on NEO-TRA1 at American Society of Hematology (ASH) Annual Meeting

November 16, 2022 | finance.yahoo.com

Neoleukin (NLTX) Stops Development of Lead Drug, Stock Down

January 31, 2023 | Porter & Company (Ad)

Is This The End of Capitalism?

EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…

November 15, 2022 | markets.businessinsider.com

Mizuho Securities downgrades Neoleukin Therapeutics (NLTX) to a Hold

November 15, 2022 | finance.yahoo.com

Neoleukin Pauses Development Of NL-201, Cuts 40% Of Employee Strength

November 15, 2022 | seekingalpha.com

Neoleukin cut to Hold at Stifel on plans to drop lead asset

November 15, 2022 | markets.businessinsider.com

5 Analysts Have This to Say About Neoleukin Therapeutics

November 15, 2022 | finance.yahoo.com

Neoleukin Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Update

January 31, 2023 | Porter & Company (Ad)

The Next Big Crisis Is Here

You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.

November 3, 2022 | finance.yahoo.com

Neoleukin Therapeutics Announces Oral Presentation at 64th American Society of Hematology (ASH) Annual Meeting

October 1, 2022 | finance.yahoo.com

We're Keeping An Eye On Neoleukin Therapeutics' (NASDAQ:NLTX) Cash Burn Rate

August 10, 2022 | seekingalpha.com

Neoleukin Therapeutics, Inc. (NLTX) CEO Jonathan Drachman on Q2 2022 Results - Earnings Call Transcript

August 10, 2022 | seekingalpha.com

Neoleukin Therapeutics, Inc. 2022 Q2 - Results - Earnings Call Presentation

August 9, 2022 | msn.com

Recap: Neoleukin Therapeutics Q2 Earnings

August 9, 2022 | finance.yahoo.com

Neoleukin Therapeutics Announces Second Quarter 2022 Financial Results & Provides Corporate Update

August 3, 2022 | finance.yahoo.com

Neoleukin Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference

July 27, 2022 | finance.yahoo.com

Neoleukin Therapeutics to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 9, 2022

July 4, 2022 | finance.yahoo.com

Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) insider upped their holding by 6.7% earlier this year

May 16, 2022 | finance.yahoo.com

Neoleukin Therapeutics Announces First Patient Treated in Combination Arm of Phase 1 Trial Evaluating NL-201 in Combination with KEYTRUDA® (pembrolizumab)

May 9, 2022 | seekingalpha.com

Neoleukin Therapeutics GAAP EPS of -$0.28 beats by $0.02

May 9, 2022 | finance.yahoo.com

Neoleukin Therapeutics Announces First Quarter 2022 Financial Results and Corporate Update

April 13, 2022 | seekingalpha.com

Neoleukin announces preclinical data for immunotherapy candidate NL-201, shares fall

April 13, 2022 | finance.yahoo.com

Neoleukin Therapeutics Announces Preclinical Data for NL-201 at American Association for Cancer Research (AACR) Annual Meeting

April 7, 2022 | finance.yahoo.com

Neoleukin Therapeutics to Present at Canaccord Genuity Horizons in Oncology Conference

March 15, 2022 | finance.yahoo.com

Neoleukin Therapeutics Announces Appointment of Donna Cochener as General Counsel

March 8, 2022 | finance.yahoo.com

Neoleukin Therapeutics Announces Multiple Presentations at American Association for Cancer Research (AACR) Annual Meeting

March 1, 2022 | benzinga.com

Recap: Neoleukin Therapeutics Q4 Earnings

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive NLTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neoleukin Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NLTX Company Calendar

Last Earnings: 11/14/2022
Today: 1/31/2023
Next Earnings (Estimated): 3/07/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:NLTX
CUSIP: N/A
CIK: 1404644
Web: www.neoleukin.com
Phone: (866) 245-0312
Fax: 778-331-4486
Employees: 91
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $6.00
High Stock Price Forecast: $10.00
Low Stock Price Forecast: $2.00
Forecasted Upside/Downside: +908.2%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.08)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-60,690,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -47.87%
Return on Assets: -41.17%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.63
Quick Ratio: 10.63

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.37 per share
Price / Book: 0.18

Miscellaneous

Outstanding Shares: 42,580,000
Free Float: 36,721,000
Market Cap: $25.34 million
Optionable: Optionable
Beta: 1.11

Key Executives

Jonathan G. Drachman
President, Chief Executive Officer, CFO & Director

Priti Patel
Chief Medical Officer

Bill Arthur
Head-Research & Vice President

Carl Walkey
Senior Vice President-Corporate Development

Sean Smith
Chief Accounting Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NLTX Stock - Frequently Asked Questions

Should I buy or sell Neoleukin Therapeutics stock right now?: 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Neoleukin Therapeutics in the last year. There are currently 1 sell rating, 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" NLTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NLTX, but not buy additional shares or sell existing shares.
View NLTX analyst ratings or view top-rated stocks.
What is Neoleukin Therapeutics' stock price forecast for 2023?: 8 analysts have issued 1-year target prices for Neoleukin Therapeutics' stock. Their NLTX share price forecasts range from $2.00 to $10.00. On average, they anticipate the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 900.0% from the stock's current price.
View analysts price targets for NLTX or view top-rated stocks among Wall Street analysts.
How have NLTX shares performed in 2023?: Neoleukin Therapeutics' stock was trading at $0.5090 on January 1st, 2023. Since then, NLTX shares have increased by 17.9% and is now trading at $0.60.
View the best growth stocks for 2023 here.
When is Neoleukin Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our NLTX earnings forecast.
How were Neoleukin Therapeutics' earnings last quarter?: Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) released its quarterly earnings data on Monday, November, 14th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.32) by $0.08.

What other stocks do shareholders of Neoleukin Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Neoleukin Therapeutics investors own include Alibaba Group (BABA), Cisco Systems (CSCO), Pfizer (PFE), Raytheon Technologies (RTX), Procter & Gamble (PG), Sorrento Therapeutics (SRNE), CVS Health (CVS), Fulcrum Therapeutics (FULC) and Home Depot (HD).
What is Neoleukin Therapeutics' stock symbol?: Neoleukin Therapeutics trades on the NASDAQ under the ticker symbol "NLTX."
Who are Neoleukin Therapeutics' major shareholders?: Neoleukin Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bros Advisors Lp Baker, Carl Walkey, Jonathan G Drachman, Priti Patel, Redmile Group, Llc, Robert Ho and Sean Michael Smith.
View institutional ownership trends.
How do I buy shares of Neoleukin Therapeutics?: Shares of NLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Neoleukin Therapeutics' stock price today?: One share of NLTX stock can currently be purchased for approximately $0.60.
How much money does Neoleukin Therapeutics make?: Neoleukin Therapeutics (NASDAQ:NLTX) has a market capitalization of $25.55 million. The company earns $-60,690,000.00 in net income (profit) each year or ($1.08) on an earnings per share basis.
How can I contact Neoleukin Therapeutics?: Neoleukin Therapeutics' mailing address is 1616 EASTLAKE AVE EAST SUITE 360, SEATTLE WA, 98102. The official website for the company is www.neoleukin.com. The company can be reached via phone at (866) 245-0312, via email at investors@neoleukin.com, or via fax at 778-331-4486.

This page (NASDAQ:NLTX) was last updated on 1/31/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Neoleukin Therapeutics - NLTX Stock Forecast, Price & News

Neoleukin Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Company Ownership

Earnings and Valuation

About Neoleukin Therapeutics (NASDAQ:NLTX) Stock

NLTX Stock News Headlines

NLTX Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

NLTX Stock - Frequently Asked Questions

Overall MarketRank^™